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High dose sequential chemotherapy with autologous
transplantation versus dose-dense chemotherapy
MegaCEOP as first line treatment in poor-prognosis
diffuse large cell lymphoma: an “Intergruppo Italiano
Linfomi” randomized trial
Patients with diffuse large-cell lym-phoma (DLCL) have a long-term curerate with cyclophosphamide, doxoru-
bicin, vincristine and prednisone (CHOP)
of 35%1 and third-generation regimens
have failed to show better results in a large
randomized clinical trial.2 To date, patients
at intermediate-high or high risk, according
to the age-adjusted International Pro-
gnostic Index (IPI) score, have a long-term
survival rate less than 30-35% if treated
with standard chemotherapy.3 High-dose
chemotherapy with autologous stem cell
transplantation (ASCT) has been proven to
be an effective salvage treatment for
chemosensitive relapsed patients.4 Many
investigators have extended this approach
as part of the initial therapy of patients
with DLCL, especially those considered at
poor prognosis, with conflicting results in
pilot and randomized studies.5-10 Recently, a
randomized trial performed in low-to-
intermediate risk patients showed that
event-free survival was better in patients
treated with high-dose chemotherapy and
ASCT than in those treated with CHOP.9 In
contrast, another trial in poor-prognosis
aggressive lymphomas at diagnosis failed to
demonstrate any benefit from high-dose
chemotherapy and ASCT compared to
standard chemotherapy.10
An alternative approach is to increase the
dose and/or shorten the interval of adminis-
tration of chemotherapy drugs delivered in
an outpatient setting without stem cell sup-
port. The doses of cyclophosphamide and
doxorubicin, or one of its analogs such as
epirubicin, may be escalated and are effec-
tive in the treatment of DLCL, although the
superiority of this strategy over standard
chemotherapy has not yet been clearly
proven.11-14 A phase II study showed that
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Background and Objectives. Poor prognosis diffuse large cell lymphoma (DLCL)
responds poorly to standard chemotherapy. Randomized studies comparing high-dose
chemotherapy with autologous stem-cell transplantation (ASCT) against standard
chemotherapy have produced conflicting results. Dose-dense chemotherapy with gran-
ulocyte colony-stimulating factor (G-CSF) support seems to hold promise. The purpose
of this multicenter, randomized trial was to compare failure-free and overall survival in
patients with poor prognosis DLCL treated with high-dose sequential (HDS) chemother-
apy followed by ASCT or an outpatient dose-dense chemotherapy regimen (MegaCEOP).
Design and Methods. Between 1996 and 2001, 130 DLCL patients, aged ≤ 60 years,
with intermediate-high or high-risk disease, according to the International Prognostic
Index score, and/or bone marrow involvement were enrolled. Sixty were randomized to
HDS chemotherapy plus high-dose mitoxantrone and melphalan with ASCT (arm A) and
66 to the MegaCEOP regimen (6-8 courses of an escalated dose of cyclophosphamide
and epirubicin plus vincristine and prednisone with G-CSF every 2-weeks) (arm B); 4
patients were considered ineligible. 
Results. The complete remission rate was 59% in arm A and 70% in arm B (p=0.18).
After a median follow-up of 78 months, the 6-year failure-free survival was 45% in arm
A and 48% in arm B (hazard ratio=1.15, 95% confidence intervals =0.72-1.84,
p=0.56). The 5-year overall survival was 49% in arm A and 63% in arm B (hazard
ratio=1.67, 95% confidence interval=0.98-2.85, p=0.06). Two cases of secondary
acute myeloid leukemia were observed after treatment in group A. 
Interpretations and Conclusions. HDS and ASCT as initial therapy for patients with
poor-prognosis DLCL does not provide a benefit over that of outpatient dose-dense
MegaCEOP chemotherapy. 
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dose-dense chemotherapy, with increased doses of
epirubicin and cyclophosphamide and shorter intervals
between courses with granulocyte-colony stimulating
factor (G-CSF) support (MegaCEOP), is feasible and
effective in the treatment of DLCL.14 Based on this
rationale, a randomized trial was designed by the
Intergruppo Italiano Linfomi to compare failure-free
and overall survival between these two approaches in
patients with advanced stage poor-prognosis DLCL. At
diagnosis, patients were randomly allocated to receive
the high-dose sequential (HDS) regimen of chemother-
apy followed by ASCT support6 or a dose-dense outpa-
tient chemotherapy regimen, MegaCEOP, with G-CSF
support.
Design and Methods
Eligibility criteria
This study was a prospective, randomized trial of the
treatment of poor prognosis DLCL conducted in four-
teen Italian hematology departments by the
Intergruppo Italiano Linfomi (see appendix). From
January 1996 to March 2001, 130 consecutive patients
affected by DLCL entered the study. Inclusion criteria
were as follows: previously untreated aggressive lym-
phoma (diffuse large B-cell, anaplastic or peripheral T-
cell lymphoma according to the REAL classification);15
age 18 to 60 years; 0-2 Eastern Cooperative Oncology
Group (ECOG) performance status (PS) of 0-2; age-
adjusted International Prognostic Index (IPI) score
defined as intermediate-high (IH) and high (H) risk;3 no
central nervous system (CNS) involvement at diagno-
sis; normal renal, cardiac, pulmonary and hepatic func-
tion; negative serology for human immunodeficiency,
hepatitis B or hepatitis C virus. Based on previous data
reported by our group, patients who had large cell bone
marrow (BM) involvement were also considered at
poor prognosis and enrolled into the study regardless of
the IPI score.16 Central pathologic review was not rou-
tinely planned, however the histological diagnosis of 71
patients was checked at the Pathology Department of
the University of Turin by DN. Details of the histolog-
ical subtypes are listed in Table 1. The trial was
approved by all institutions’ ethics committee and all
patients gave their written informed consent to partici-
pation.
Staging
Staging included physical examination, computed
tomography of the chest, abdomen and pelvis, cerebral
spinal fluid examination, bone marrow biopsy, blood
cell counts and differential, routine blood chemistry,
and MUGA scans or echocardiography. Bulky disease
was defined as a mass > 10 cm in one diameter or more
than one-third of the chest diameter in the medi-
astinum. PS and toxicity were assessed according to the
ECOG scale and WHO toxicity criteria grading system,
respectively.
Treatment plan
Patients were centrally randomized by fax
between the HDS regimen followed by ASCT6 (arm
A) and outpatient MegaCEOP chemotherapy regi-
men (arm B). The randomization sequence was gen-
erated by the co-ordinating center using a random-
number table and stratified for participating center
and BM involvement. Randomization was concealed
U. Vitolo et al.
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Table 1. Initial characteristics of the patients according to treat-
ment group: HDS + ASCT versus MegaCEOP.
Characteristic Arm A: HDS + ASCT Arm B: 
(n = 60) (n = 66)
No. of % No. of %
patients patients
Median age, years (range) 42 (18-59) 43 (18-60)
Gender
Male 35 58 37 56
Female 25 42 29 44
Histological sub-types
Diffuse large B-cell 48 80 59 90
Primary mediastinal B-cell 6 10 4 6
Peripheral T-cell 4 7 2 3
Anaplastic large cell 2 3 1 1
B symptoms*
Absent 18 30 30 45
Present 42 70 36 55
Performance status grade
0-1 22 37 29 44
>1 38 63 37 56
Ann Arbor stage
II 16 26 12 18
III 13 22 14 21
IV 31 52 40 61
No. of extranodal sites
0-1 45 75 52 79
≥ 2 15 25 14 21
Bone marrow involvement
Absent 47 78 48 73
Present 13 22 18 27
Tumor bulk*
Absent 24 40 38 58
Present (>10 cm) 36 60 28 42
Serum LDH level
< normal 15 25 17 26
≥ normal 45 75 49 74
Age-adjusted IPI risk
Low-Intermediate 8 13 13 20
Intermediate-High 31 52 28 42
High 21 35 25 38
* The difference is statistically significant p<0.05. 
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until the interventions were assigned. The trial
design is shown in Figure 1. Arm A consisted in three
phases: 1) doxorubicin 50 mg/m2 on day 1, vincristine
1.4 mg/m2 (maximum 2 mg) on days 1, 8 and 15,
prednisone 40 mg/m2 from day 1 to 21 (APO regi-
men); 2) sequential administration, at 15-21 day
intervals, of three single high-dose chemotherapy
courses with cyclophosphamide 7 g/m2 plus G-CSF 5
µg/Kg/day (Filgrastim, Amgen/Roche, Milan, Italy)
from day 2 until the peripheral-blood stem cell
(PBSC) harvest, methotrexate 8 g/m2 + vincristine 1.4
mg/m2 (maximum 2 mg) with leucovorin rescue and
etoposide 2 g/m2 plus G-CSF 5 µg/Kg/day from day 4
until recovery of neutrophil counts; 3) mitoxantrone
60 mg/m2 on day – 5 and melphalan 180 mg/m2 on
day – 2 followed by ASCT. Patients with BM
involvement were given a modified HDS regimen as
follows: two courses of APO; an inverted sequence
with methotrexate, etoposide, two additional cours-
es of DHAP17 in case of less than partial response or
persistence of BM involvement and cyclophos-
phamide + G-CSF with PBSC harvest. Patients ran-
domized to arm A with no response after the HDS
regimen or progressive disease at any time did not
proceed to ASCT. 
Arm B consisted in epirubicin 110 mg/m2 on day 1,
cyclophosphamide 1200 mg/m2 on day 1, vincristine
1.4 mg/m2 (maximum 2 mg) on day 1, and pred-
nisone 40 mg/m2 from day 1 to 5 at 2-week inter-
vals.14 G-CSF support (5 µg/Kg/day) was given from
day 2 to day 10. In case of neutropenia < 1.5×09/L
chemotherapy was delayed for one week. No dose
reduction or delays were allowed in the case of
thrombocytopenia, but platelet transfusions were
given if the platelet count was <15×09/L. Patients in
complete remission after four courses of MegaCEOP
chemotherapy received two additional courses,
those in partial remission or stable disease were
given four additional courses. Patients with BM
involvement always received eight courses of
Figure 1. Treatment schema and flow through the study of the 130 patients: arm A: high
dose sequential (HDS) regimen followed by autologous stem cell transplantation (ASCT);
arm B MegaCEOP chemotherapy regimen. Numbers of patients at each stage of therapy
are indicated in the boxes. AA-IPI, age-adjusted International Prognostic Index; BM+,
bone marrow involvement; PBSC, peripheral blood stem cell harvest; IF RT, involved field
radiotherapy; HD: high dose; APO: doxorubicin, vincristine and prednisone; HD-CTX: HD
cyclophosphamide; HD-VP: HD vepesid; VCR + HD-MTX: vincristine plus HD methotrexate;
DHAP: cisplatinum, cytarabine and dexamethasone; HD-Mitox and HD-L-PAM: HD mitox-
antrone and melphalan; MegaCEOP: cyclophosphamide, epirubicin, vincristine and pred-
nisone. See text for drug doses and schedule. 
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MegaCEOP. Patients with BM, testicular or paranasal
sinus involvement were given CNS prophylaxis with
intrathecal methotrexate 12 mg/m2; four doses were
given in arm A and six doses in arm B. At the end of
the treatment, radiotherapy (36 Gy) was given to
areas of previous bulky disease.
Stem cell harvesting
At least 3×106/Kg peripheral blood CD34+ cells
were collected after cyclophosphamide. In the case
of inadequate PBSC collection, stem cells were har-
vested from the BM.
Supportive care
Patients randomized to group A were given the
entire program in standard, non-protected rooms.
Patients randomized to group B received their treat-
ment in an outpatient setting.
Assessment of response
An intermediate assessment of response was
planned in each arm. In arm A patients were restaged
before ASCT. Those with BM involvement under-
went an additional earlier revaluation, including BM
biopsy, after high dose etoposide in order to decide-
whether or not to administer two additional courses
of DHAP. In arm B patients were revaluated after
four courses of the MegaCEOP regimen. In both
arms, the final response assessment was performed
one month after the end of the whole therapeutic
program. Complete remission (CR) was defined as
the absence of any detectable clinical and radiograph-
ic disease with disappearance of all disease-related
symptoms. Unconfirmed complete remission (CRu)
was considered as a persistent clinical or radiograph-
ic lymph-node mass that regressed by more than
75% of the initial tumor volume and no signs or
symptoms of active disease. If the radiological abnor-
malities were subsequently stable for at least three
months the patients were judged to have a CR.
Patients with a 50% or greater reduction in tumor
volume were considered in partial remission (PR). No
response was defined as anything less than a PR or
progressive disease or any death during the treat-
ment period.18
Study design and statistical methods
The primary endpoint of the study was failure-free
survival (FFS), with failure defined as an incomplete
response, relapse or death from any cause and was
used to determine the sample size of the study. The
study was designed according to data on the HDS
regimen available in 1996 that showed a clear advan-
tage for FFS in favor of high-dose chemotherapy with
ASCT compared to standard chemotherapy.6 The
main hypothesis of the study was to confirm these
results and detect an increase of 25% in the probabil-
ity of FFS at 3 years in favor of the HDS+ASCT arm.
With a two-sided α error of 0.05 and a β error of 0.20
and assuming a 50% 3-year FFS in the MegaCEOP
arm versus an expected 75% in the HDS+ASCT arm,
this design required the randomization of 62 patients
per arm and an estimated time of about 5 years to
reach these numbers. Secondary endpoints were
overall survival (OS) and clinical response.
All the randomized patients were considered
assessable and results were analyzed on an intention-
to-treat basis. Analysis was based on disease status in
November 2004 with a minimum of 3 years of fol-
low-up. All survival and failure-free times were cen-
sored at the closing date or the date of last contact,
whichever came first. The FFS analysis included all
patients and was calculated from the date of diagno-
sis to the date of incomplete response, relapse, pro-
gression or death from any cause or last follow-up
without any event. The OS analysis included all
patients, and death due to any cause; OS was meas-
ured from the date of diagnosis to the date of death
or last follow-up alive. Disease-free survival (DFS)
was applied only to patients who achieved a CR/Cru
and was calculated from the time of CR/CRu assess-
ment to the date of relapse or last follow-up free of
disease. All curves were plotted according to the
method of Kaplan and Meier19 and statistical differ-
ences among curves were evaluated by the log rank
test. The Cox proportional hazard model was used to
estimate hazard ratios (HR) and corresponding 95%
confidence intervals (95% CI), adjusted for unbal-
anced or important prognostic factors (BM involve-
ment, IPI score).20
The proportions of responses and toxic effects
were compared between the two arms by a χ2 test or
Fisher’s exact test, depending on the size of the sam-
ple evaluated. Means were compared by two sided t-
tests. All calculations were done using the SAS (v. 8.2)
package.
The data were collected by one investigator at each
participating center, sent to the centralized database
in Turin and checked for accuracy by hematology
research assistants at the University of Turin.
Results
Patients’ characteristics
One hundred and thirty patients were randomized.
During the first cycle of therapy four patients, two in
each arm, were found to violate the entry criteria and
were therefore excluded. Of these, two had CNS
involvement at diagnosis and two had Burkitt’s lym-
phoma at histological revision. Thus 126 patients
were considered eligible: 60 were randomized to
U. Vitolo et al.
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receive HDS + ASCT (arm A) and 66 MegaCEOP
chemotherapy (arm B). The clinical characteristics of
the 126 patients are listed in Table 1 and were well
balanced between the two arms, except for an excess
of patients with bulky disease and B symptoms in
the HDS+ASCT group.
Feasibility
Overall 110 (87%) patients completed the assigned
treatment. Fifty-nine of 64 patients who had bulky
disease at diagnosis completed the chemotherapy
treatment. Consolidation radiotherapy to previous
bulky areas was delivered to patients who complet-
ed the chemotherapy: 20 of 32 (62%) patients with
bulky disease in arm A and 20 of the 27 (74%)
patients in arm B (p=0.34).
Arm A. Fifty (83%) of the 60 patients completed the
treatment and underwent ASCT; the source of stem
cells was peripheral blood in 47 patients and autolo-
gous BM cells in the other 3 patients. Reasons for not
completing the planned treatment in 10 patients
were: disease progression before ASCT in 8 patients,
acute congestive heart failure after two courses of
APO in one and toxic death in one. Five patients with
BM involvement received two additional courses of
DHAP because of persistence of BM involvement or
less than PR after high dose etoposide.
Arm B. Four hundred and forty-one courses of
MegaCEOP chemotherapy were delivered with a
mean of 6.7 courses per patient. Sixty (92%) of 66
patients completed the planned MegaCEOP
chemotherapy. Six interrupted the treatment: 4
because of progressive disease and 2 because of toxic
deaths.
Response to treatment and outcome
Thirty-five (59%) patients achieved CR + CRu in
arm A and 46 (70%) in arm B (p=0.18). Partial remis-
sion was documented in 6 (10%) patients in arm A
and in 6 (9%) in arm B, while during treatment 17
(28%) patients in arm A and 12 (18%) in arm B pro-
gressed. Two patients in each arm (3%) died of toxi-
city.
After a median follow up of 78 months, treatment
had failed in 70 patients (arm A 34, arm B 36) and 55
died (arm A 31, arm B 24). There was no statistically
significant difference in 5-year FFS between the two
groups: 45% for arm A and 48% for arm B, with a
crude hazard ratio (HR)=1.15 (95% CI=0.72-1.84,
p=0.56) (Figure 2A).
There was a trend for a lower 6-year overall sur-
vival rate in arm A (49%) than in arm B (63%), with
a crude HR=1.67 (95% CI=0.98-2.85, p=0.06) (Figure
2B). Relapses were observed in 9 of the 35 patients
who had achieved CR in arm A and in 16 of the 46
with CR in arm B, thus the 6-year DFS rates were
72% in arm A and 69% in arm B, with a crude
HR=0.69 (95% CI=0.31-1.56, p=0.37). A Cox’s model
was performed to adjust the effect of the treatment
for potential confounders such as B symptoms and
bulky disease, included into the model due to their
unbalanced distribution between the two arms, and
BM involvement and age-adjusted IPI score, included
as main prognostic factors. In this multivariate analy-
sis, FFS was not affected by treatment, with an
adjusted HR (arm A vs. arm B)= 1.17 (95% CI=0.72-
1.89, p=0.53), while a higher age-adjusted IPI score
showed a tendency to increase the failure risk, with
an adjusted HR (for each point of IPI score)=1.38
(95% CI 0.97–1.97, p=0.07).
In the multivariate analysis overall survival was
marginally affected by treatment, with an adjusted
HR (arm A vs. arm B)=1.67 (95% CI 0.96 - 2.90,
p=0.07). The age-adjusted IPI score was a strong pre-
Chemotherapy in DLCL
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A
B
Figures 2A, B. 6-year FFS (a) and OS (b) according to the treat-
ment arm. Arm A (HDS + ASCT); Arm B (MegaCEOP). A. FFS at
six years: 45% (Arm A) vs. 48% (Arm B) p=0.52 B. OS at six years:
49% (Arm A) vs. 63% (Arm B) p=0.06. 
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dictor of death: adjusted HR (for each point of IPI
score)=1.83 (95% CI 1.20 - 2.79, p=0.005). A not pre-
specified subgroup analysis for patients with inter-
mediate-high and high risk scores (arm A, n = 52; vs.
arm B, n=53) did not reveal any statistically signifi-
cant differences between the two treatment arms:
FFS 44% vs. 45% (adjusted HR=1.16, 95% CI=0.69-
1.98, p=0.57) and OS 48% vs. 58% (adjusted
HR=1.59, 95% CI=0.89-2.85, p=0.12). No differences
in 5-year FFS and OS were observed between the
two treatment arms in patients with or without BM
involvement (data not shown).
Failures and relapses
Treatment failed in 34 patients in arm A and 36 in
arm B. Patients who did not respond or relapsed after
remission received different salvage chemotherapy
regimens. Of the 34 patients in arm A in whom treat-
ment failed, 27 died of progressive disease, 2 died of
toxicity during primary treatment, 2 died of second-
ary acute non-lymphoblastic leukemia (ANLL) and 3
are alive. Treatment failed in 36 patients in arm B: 22
died of progressive lymphoma, 2 of toxicity during
primary treatment and 12 are alive. The 2-year sur-
vival from the date of relapse or progression was sig-
nificantly lower for arm A (12%) than for arm B
(33%), with a crude HR=2.41 (95% CI 1.40-4.15,
p=0.0015) (Figure 3).
Toxicity
All 50 patients who underwent ASCT with high
dose mitoxantrone and melphalan in arm A achieved
complete hematologic engraftment with neutrophil
counts > 0.5×109/L after a median of 11 days (range,
6 to 30 days) and a self-sustaining platelet count >
50×109/L after a median of 12 days (range, 5 to 98
days). Twenty-seven per cent required packed red
cell transfusions during the HDS regimen and 86%
after ASCT. Platelet concentrates were given to 18%
of the patients during the HDS regimen and 88%
after ASCT.
MegaCEOP chemotherapy in arm B was delivered
in an outpatient setting. In this study group grade 4
hematologic toxicity for neutrophils, platelets and
hemoglobin was recorded in 22%, 2% and 1.4% of
the total delivered courses and occurred in 48%, 3%
and 1.5% of the patients, respectively. Packed red cell
transfusions and platelet concentrates were given to
43% and 6% of the patients, respectively. 
There were four toxic deaths, all infection-related,
two in each arm. In arm A, one patient died of pul-
monary aspergillosis after APO chemotherapy and
the second one died of neutropenic sepsis after
ASCT. In arm B two fatal infections (neutropenic sep-
sis and a bilateral bacterial pneumonia) occurred dur-
ing treatment. Severe non-hematologic toxicities,
WHO grade 3 or 4, are reported in Table 2.
Two cases of secondary ANLL or myelodysplastic
syndrome (MDS) occurred at 23 and 30 months after
ASCT in arm A. Both patients were in CR of their
lymphoma and died of secondary leukemia.
Discussion
The aim of this Intergruppo Italiano Linfomi ran-
domized trial was to assess the potential benefit of a
HDS chemotherapy regimen with ASCT support com-
Table 2. WHO grade 3-4 toxicity: HDS + ASCT versus MegaCEOP.
Type of toxicity Arm A: HDS + ASCT Arm B: MegaCEOP
(n = 60) (n = 66)
HDS ASCT HDS + ASCT* No of pts. %
(n = 60)(n = 50) (n = 60)
No of pts. %
Severe infections 9 11 17 28 6 9
Mucositis 4 18 22 37 2 3
Cardiac 2 1 3 5 1 2
Neurological 2 1 3 5 3 5
Gastro-intestinal 5 4 9 15 5 8
Renal 1 1 2 3 1 2
Acute toxic deaths 1 1 2 3 2 3
Secondary _ _ 2 3 0 0
MDS/ANLL
*N. and percentage of patients who showed grade 3-4 toxicity in HDS or ASCT
phase.
Figure 3. OS of patients who relapsed or had disease progression
and had been treated with HDS+ASCT or MegaCEOP. OS was cal-
culated from the date of relapse or progression. OS at two years:
12% (Arm A) vs. 33% (Arm B) p=0.0015.
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pared to a dose-dense outpatient MegaCEOP
chemotherapy regimen with G-CSF support in patients
with de novo poor prognosis aggressive lymphoma.
Unlike some other trials dealing with this issue,
patients were randomized up-front between two com-
pletely different regimens in order to properly evaluate
the role of high dose chemotherapy with ASCT as ini-
tial treatment. The present study failed to show any
advantage of HDS and ASCT in this group of patients
and acute toxicities such as mucositis and infections
were reported less frequently in the MegaCEOP arm.
The CR rate was higher, although not to a statistically
significant extent (70% vs. 59%), in patients treated
with MegaCEOP chemotherapy, which is intensively
delivered every two weeks. No differences in relapse
rates were observed and the 6-year actuarial FFS rates
(45% vs. 48%) were not different between the two
arms. The results of the adjusted comparisons in the
Cox’s model for FFS confirmed the lack of difference in
the outcome between HDS+ASCT and MegaCEOP
chemotherapy, excluding a confounding effect of a
slightly unbalanced distribution between groups of a
few prognostic variables. Our trial protocol allowed
the inclusion of patients at low-intermediate risk if
they had large cell BM involvement; however, after
excluding this small group of patients (17%), the results
did not change. Moreover there was a strong sugges-
tion that patients treated with MegaCEOP chemother-
apy have a more prolonged overall survival than those
who receive HDS and ASCT (63% vs. 49%) (p=0.06).
This may be due to a more effective salvage therapy for
patients who failed MegaCEOP chemotherapy, leading
to a 2-year survival rate from progression or relapse of
33% compared to only 12% for patients in whom HDS
failed. Similar data from other randomized studies
were reported and underscore the extreme difficulty of
effectively salvaging high-risk patients after high-dose
chemotherapy has failed.10,21
Some issues must be pointed out in order to explain
the results of the present trial. Firstly, 17% of the
patients in arm A did not receive ASCT, whereas in
arm B only 9% of patients interrupted the planned
MegaCEOP chemotherapy. The difficulty in delivering
high-dose chemotherapy with ASCT has been report-
ed in other randomized studies and is in the range
between 26% and 40%.8,10,21,22
It is noteworthy that in both arms of our study the
main reason for not completing therapy was induction
failure, which occurred more frequently in the trans-
plantation arm. Secondly, the results obtained in arm A
with the HDS chemotherapy regimen were worse than
expected given previously published data on the same
treatment, although the HDS regimen was applied
exactly as described.6 Our study was prospectively
designed for poor prognosis patients who had either an
intermediate-high or high risk IPI score or BM involve-
ment at the time of diagnosis. Patients who met these
criteria at the participating centers were enrolled and
analyses were performed on an intention-to-treat basis,
whereas in the trial by Gianni et al.6 IPI was determined
retrospectively, thus the patient populations may be
different and not limited to patients with a poor prog-
nosis.
A number of trials have been conducted to evaluate
the benefit of high-dose chemotherapy with ASCT as
first line treatment in aggressive lymphomas, but con-
troversy still exists regarding the impact of this strate-
gy. Differences in inclusion criteria, selection not
always based on the IPI score, various drugs schedules
and different durations of the pre-ASCT chemotherapy
phase could be responsible for the discrepancies report-
ed.6,8,21-22 Recently, Milpied et al.9 showed an advantage
in terms of event-free survival for high-dose
chemotherapy with ASCT compared to standard
CHOP in a randomized cohort of 207 patients with
aggressive lymphoma. However the advantage was
limited to low-to-intermediate risk patients because
high-risk patients were excluded from the trial and the
high-dose chemotherapy started with two courses of a
dose-dense CEEP regimen that might have contributed
to the better outcome. In another trial by the GELA
group, 370 patients were randomized at diagnosis to an
abbreviated course of induction chemotherapy fol-
lowed by BEAM and ASCT or four courses of intensi-
fied chemotherapy with ACVB at 2-week intervals
with filgrastim support, followed by consolidation
with standard chemotherapy.10 Interestingly, this study
which employed ACVB, a regimen similar to the
MegaCEOP used in our trial, demonstrated a benefit in
term of overall and event-free survival (EFS) for
patients treated with the ACVB regimen.
An outpatient dose-dense CHOP-like regimen with
G-CSF support may be an alternative strategy to high-
dose chemotherapy in patients with poor-risk aggres-
sive lymphoma and promising results have been
reported in phase II studies.11-14,23-24 On the other hand a
prospective trial failed to show that increasing dose
intensity influences outcome.25 Recently, three random-
ized trials showed that increased doxorubicin and
cyclophosphamide doses or decreased intervals
between cycles could improve treatment results.26-28 In
a GELA trial, the ACVB regimen was reported to pro-
duce a better 5-year EFS and OS compared to standard
CHOP chemotherapy, although this study was limited
to elderly patients and also included patients at low-
intermediate risk.26 The German Lymphoma Study
Group reported that the addition of etoposide to
CHOP, mainly at decreased intervals (CHOEP-14),
improved CR, 5-year EFS and OS compared to CHOP-
21 in young patients with aggressive lymphomas and a
U. Vitolo et al.
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good prognosis (normal lactate dehydrogenase levels)
and shortening the intervals between cycles (CHOP-
14) improved 5-year EFS and OS in elderly patients.27-28
However dose-dense chemotherapy regimens may
have more acute or long-term side effects as reported
by some authors.11,26 Thus, this strategy may be as effec-
tive as high-dose chemotherapy with ASCT, but its
potential benefit over standard chemotherapy remains
to be clearly demonstrated, particularly in young
patients at intermediate-high or high risk. In the pres-
ent study, two patients treated with HDS chemothera-
py and ASCT developed a secondary ANLL or MDS.
Although this figure is in the range of those reported
after high-dose chemotherapy, its occurrence in
patients CR is worrisome.29
One important limit of our study should be high-
lighted. Our trial was designed to detect a 25%
increase of probability of 3-year FFS in favor of the
transplantation arm, based on previous data with the
HDS + ASCT regimen reported by Gianni et al. from 98
patients who showed an event-free survival rate of
76% for HDC with ASCT compared to 49% for stan-
dard chemotherapy.6 The sample size of the present
trial was calculated with a two-sided test based on
these expected figures. However the results of other
trials that were reported in the following years, when
our study was ongoing, did not confirm these excellent
results in favor of high-dose chemotherapy. Thus our
trial was clearly underpowered and unable to detect
smaller differences between treatment arms, such as
the suggested survival advantage among recipients of
the dose-dense chemotherapy, which might have been
evident if the study had been designed for a smaller dif-
ference in a larger cohort of patients. 
The proper role and place of high-dose chemothera-
py and ASCT as part of first line treatment in poor risk
DLCL remains a controversial issue. Increasing the CR
rate remains the main aim to improve the outcome of
patients with poor prognosis aggressive lymphoma.
The addition of rituximab has proven to increase the
effectiveness of standard CHOP chemotherapy signifi-
cantly and may reduce lymphoma cell contamination
from stem cell harvests as an in vivo purging agent
before ASCT.30-31 High-dose chemotherapy with ASCT
might be better at prolonging remission duration in CR
patients at high and intermediate-high risk when this
strategy is used after maximum tumor reduction has
been achieved with a full course of chemotherapy.32-33
However, in order to avoid over-treatment and long-
term morbidity, its value as up-front therapy needs to
be weighed against standard or dose-dense outpatient
chemotherapy in combination with anti-CD20 as first
line treatment, with the option of high-dose
chemotherapy and ASCT as salvage therapy in cases of
failure.4 A dose-dense outpatient chemotherapy regi-
men, likely with concurrent rituximab, may be a feasi-
ble and effective alternative approach to improve the
prognosis of poor risk DLCL. 
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